Evidence map›Paper›PMID 39596188›Full record

ArticleInternational journal of molecular sciences2024

Identifying an Inversin as a Novel Prognostic Marker in Patients with Clear-Cell Renal Cell Carcinoma.

Ivanka Urlić, Violeta Šoljić, Martina Vukoja, Inga Marijanović, Marija Kraljević, Marjan Urlić, Sara Marić, Katarina Vukojević, Natalija Filipović

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ivanka UrlićDepartment of Oncology and Radiotherapy, University Hospital of Split, 21000 Split, Croatia.
Violeta ŠoljićLaboratory of Morphology, Department of Histology and Embryology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and Herzegovina.
Martina VukojaLaboratory of Morphology, Department of Histology and Embryology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and Herzegovina.
Inga MarijanovićClinic of Oncology, University Clinical Hospital Mostar, 88000 Mostar, Bosnia and Herzegovina.
Marija KraljevićClinic of Oncology, University Clinical Hospital Mostar, 88000 Mostar, Bosnia and Herzegovina.
Marjan UrlićDepartment of Cardiac Surgery, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-0741-9333
Sara MarićOdjel za Patološku Anatomiju i Citologiju, Kantonalna Bolnica Dr. Safet Mujić, 88000 Mostar, Bosnia and Herzegovina.
Katarina VukojevićLaboratory of Morphology, Department of Histology and Embryology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and Herzegovina.ORCID 0000-0003-2182-2890
Natalija FilipovićDepartment of Anatomy, Histology and Embryology, University of Split School of Medicine, 21000 Split, Croatia.ORCID 0000-0002-8943-4109

Funding

Croatian Science Foundation IP-2022-10-7321
6 · The paper itself

Abstract

Precision medicine is a developing trend in oncology, and it includes the prognosis and treatment of advanced-stage ccRCC. New predictive factors and therapeutic targets for this disease are steadily needed. The aim of this study was to explore the tumor expression of inversin as a potential prognostic factor and/or therapeutic target in ccRCC. We compared the expression of inversin between primary ccRCC and normal renal tissues by using immunohistochemistry and rtPCR in our cohort, and we also analyzed publicly available data from the TCGA-KIRC cohort. We found that the expression of inversin was significantly lower in primary tumor tissue, in comparison to solid normal tissue. Data from the KIRC study confirmed that a lower

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, Tumorclear-cell renal cell carcinomainteractomeinversinprognosistarget

Identifiers

PMID39596188
PMCPMC11594840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.